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1. Introduction 
Suicide is a major public health issue and a significant cause of death worldwide. Most 
suicides (about 90%) occur in the context of psychiatric disorders, most commonly major 
depressive disorder, which is associated with approximately 60% of all suicides (Carlson et 
al. 1991). Prediction of suicidal risk in major depressive disorder is very important for 
preventing suicide, but current approaches to predicting suicidal behavior are based on 
clinical history and have low specificity. Accordingly, biological markers may provide a 
more specific means of identifying individuals at high risk of suicide with major depressive 
disorder (Lee and Kim 2011). Despite the high lifetime rate of suicide in patients with major 
depressive disorder (estimated to be 10-15%; Wulsin et al. 1999), most never attempt suicide. 
This raises the question of why some people with major depression are at risk of suicide and 
others are not, and suggests that the predisposition toward suicidal behavior is independent 
of psychiatric disorders. Other factors that increase the risk of suicidal behavior include 
psychosocial stressors, aggressive and impulsive traits, hopelessness, pessimism, substance 
abuse and dependence, physical or sexual abuse during childhood, and a history of head 
injury or neurological disorders. In considerations of these risk factors, suicidal behavior has 
been conceptualized into stress-diathesis and state-trait interaction models (Mann et al. 
1999; Van Heeringen and Marusic 2003). Figure 1 illustrates the stress-diathesis model of 
suicidal behavior.  
These models suggest that acute psychological stressors act on the diathesis, or traits of 
suicidal behavior, and that the complicated interactions between stress and diathesis 
gradually evolve into suicidal behavior over time. Previous research has explored potential 
biological markers and predictors of suicide and suicidal behavior, especially in the context 
of major depression. Although work in this area has been inconclusive, many animal, post-
mortem, clinical, and genetic studies have produced results implicating at least 3 
neurobiological systems in the pathogenesis of suicidal behavior in major depression: 
deficiency in the serotonergic system, hyperactivity of the hypothalamic-pituitary-adrenal 
axis, and decreased brain derived neurotrophic factor (BDNF) metabolism. Additionally, 
other neurotransmitters, cholesterol, nitric oxide (NO) and cytokines may be associated with 
suicide and suicidal behavior in major depression. Specifically, diathesis or trait-dependent 
risk factors are associated with dysfunctions in the serotonin system; however, the stress 
response (i.e., state-dependent factors) is related to hypothalamic-pituitary adrenal(HPA)  
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Fig. 1. Stress-diathesis model of suicidal behavior 
axis hyperactivity. Decreases in cholesterol and BDNF levels are associated with impaired 
brain plasticity among individuals with suicidal behavior in major depressive disorder. In 
this chapter, I discuss peripheral biological markers involved in the pathogenesis of suicidal 
behavior in major depressive disorder and propose a model to predict the risk of suicidal 
behavior in these patients. 
2. The neurotransmitter system 
2.1 Serotonin 
The serotonin system has been widely investigated in studies of major depression and 
suicide. The innervations of the serotonin system project from the dorsal raphe nucleus to all 
of the regions of the brain, including the cerebral cortex and hippocampus. Decreased 
function and activity of the serotonergic system in suicide victims and patients with major 
depression who attempt suicide have been confirmed in postmortem, serotonin transporter, 
serotonin receptor and cerebrospinal fluid (CSF) studies and neuroendocrine challenge tests. 
Post-mortem studies of the brains of suicide victims provide evidence of reduced serotonin 
transporter sites in the prefrontal cortex, hypothalamus, occipital cortex and brainstem 
(Purselle and Nemeroff 2003). In an autoradiographic study, this abnormality was found to 
be localized to the ventromedial prefrontal cortex (Arango et al. 1995). Abnormalities were 
also observed at the receptor level, as postsynaptic 5-HT1A and 5-HT2A receptors were 
found to be upregulated in the prefrontal cortex. It has been hypothesized that this increase 
may be a compensatory mechanism to counter the low activity of serotonergic neurons 
(Mann 2003). It is interesting to note that this serotonin dysfunction appears to be localized 
to the ventral prefrontal cortex, a region that is involved in behavioral and cognitive 
inhibition. Thus, low serotonergic input may contribute to impaired inhibition, creating a 
greater propensity to act on suicidal or aggressive feelings (Mann 2003).  
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Tryptophan hydroxylase (TPH), which has two isoforms (TPH1 and TPH2), is one of the 
rate limiting factors in serotonin synthesis, Postmortem studies have reported significantly 
higher numbers and higher densities of TPH immunoreactive neurons in the dorsal raphe 
nuclei of depressed suicide victims (Underwood et al. 1999) and in the same regions of 
alcohol dependent, depressed suicide victims (Bonkale et al. 2006) when compared to 
controls. We have found that the TPH2 -703G/T SNP may have an important effect on 
susceptibility to suicidal behavior in those with major depressive disorder. Additionally, an 
increased frequency of the G allele of the TPH2 SNP is associated with elevated risk of 
suicidal behavior itself rather than with the diagnosis of major depression, and may increase 
the risk of suicidality, independent of diagnosis (Yoon and Kim 2009). Collectively, TPH, 
serotonin transporter, and serotonin receptor studies suggest that deficient or impaired 
serotonin activity is involved in suicidal behavior. Increased activity in TPH and 
postsynaptic 5-HT2A receptors may be compensatory results of decreased central levels of 
serotonin. Notably, serotonin dysfunction appears to be localized in the ventral prefrontal 
cortex among suicide victims (Mann et al. 2000), as well as in individuals who make suicide 
attempts (Leyton et al. 2006).  
The prefrontal cortex has been implicated in both behavioral and cognitive inhibition, as 
well as in willed action and decision-making. A meta-analysis examining 27 prospective and 
retrospective reports found that individuals who attempt suicide, and particularly those 
who use violent methods, had lower cerebrospinal fluid 5-hydroxyindoleacetic acid (CSF 5-
HIAA) levels when compared to psychiatric controls (Lester 1995). Additionally, a meta-
analysis of prospective biological studies estimated the odds ratio for the prediction of 
suicide completion to be 4.5-fold greater for individuals with low levels of CSF 5-HIAA than 
individuals with high levels of CSF 5-HIAA among patients with mood disorders (Mann et 
al. 2006). CSF 5-HIAA may serve as a predictor of future suicide attempts and completions, 
as findings associating CSF 5-HIAA levels with suicidal behavior have been relatively 
consistent. Additionally, levels of CSF 5-HIAA are relatively stable and therefore believed to 
be under substantial genetic control (Rogers et al. 2004). Blunted prolactin response to the 
fenfluramine challenge test has been observed among young (<30 years) inpatients with 
major depression and histories of suicide attempts (Mann et al. 1995). Other work has 
shown significantly lower prolactin responses to fenfluramine challenge tests among 
depressed patients with histories of suicide attempts than among patients without such 
histories or healthy controls (Correa et al. 2000; Mann et al. 1995). Further, decreased 
prolactin response has been reported among patients with histories of high-lethality suicide 
attempts (Malone et al. 1996). These results suggest that blunted prolactin response to 
fenfluramine, which indicates reduced serotonin function, may serve as a marker for 
suicidality among individuals with major depressive disorder.  
2.2 The noradrenergic and dopaminergic systems 
Few post-mortem studies have examined alterations in the noradrenergic or dopaminergic 
systems in suicide victims. Studies have found decreased noradrenalin (NA) levels in the 
brainstem and increased α2-adrenergic receptor densities in suicide victims (Ordway et al. 
1994a). One study found that tyrosine hydroxylase (TH), the rate-limiting enzyme for NA 
and dopamine (DA) synthesis, is higher in suicide victims (Ordway et al. 1994b), however 
another study found the opposite (Biegon and Fieldust 1992). Increased TH and α2-
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adrenergic receptor densities could be indicative of noradrenergic depletion compensatory 
to increased NA release. Increased NA release may be explained by the relationship 
between the noradrenergic system and stress response, as severe anxiety and agitation are 
associated with noradrenergic overactivity, higher suicide risk, and overactivity of the 
hypothalamic-pituitary-adrenal (HPA) axis (Mann 2003).  
Few studies have examined the dopaminergic system. Overall, no alterations were found in 
mRNA levels of the D1, D2 and D4 receptors that bind in the caudate nuclei of suicide 
victims (Hurd et al. 1997; Sumiyoshi et al. 1995). A recent investigation exploring 
homovanillinic acid (HVA) in the CSF of depressed suicide attempters found reduced HVA 
levels in attempters, but not in depressed non-attempters (Sher et al. 2006). Thus, the 
dopamine system seems to be hypofunctional in major depression (Kapur and Mann 1992).  
3. Neurotrophic factors 
3.1 Brain derived neurotrophic factor (BDNF) 
Neurotrophic factors including BDNF, nerve growth factor (NGF) and neurotrophin (NT)- 3, 
4/5, play an important physiological role in the maintenance and growth of neurons and 
synaptic plasticity in the adult brain (Lewin and Barde 1996) and are known to be involved 
in the pathogenesis of depression and suicide (Duman et al. 1997; Nestler et al. 2002). In 
particular, BDNF mRNA expression levels are significantly decreased in animals subjected 
to forced swimming and chronic immobilization stress (Russo-Neustadt et al. 2001; Xu et al. 
2002). Moreover, chronic antidepressant treatment increases the expression of BDNF and 
neurogenesis in adult rat hippocampi (Duman et al. 1997; Malberg et al. 2000). Several 
clinical studies have found differing BDNF levels in the blood sera or plasma of patients 
with major depression and patients who have attempted suicide. Deveci and colleagues 
(2007) investigated serum BDNF levels among suicide attempters without major psychiatric 
disorders, patients with major depression, and healthy subjects. They found that serum 
BDNF levels were lower among both suicide attempters and depressed patients than among 
healthy controls. Our research group has also examined plasma BDNF levels among 
patients with major depression who both have and have not attempted suicide. One study 
found that plasma BDNF levels were significantly lower among depressed patients than 
among normal controls (Lee et al. 2007). Plasma BDNF levels were also significantly lower 
among suicidal patients than non-suicidal patients with major depression, and that suicidal 
patients had the lowest levels of BDNF among all of the groups assessed (Lee et al. 2007). 
Further, Kim and colleagues (2007b) measured plasma BDNF levels in patients with 
depression who had recently attempted suicide, non-suicidal patients with depression, and 
healthy controls. BDNF levels were significantly lower among suicidal patients with 
depression than non-suicidal patients with depression and healthy controls. However, 
BDNF levels did not differ between individuals who made fatal and nonfatal suicide 
attempts (Kim et al. 2007b). One study examining BDNF mRNA expression in peripheral 
blood mononuclear cells revealed that patients with major depression and recent suicide 
attempts had decreased BDNF mRNA expression, compared to patients who had not 
attempted suicide (Lee and Kim 2010). Measurements of BDNF levels in sera or plasma in 
previous studies have been challenged, as it is questionable whether BDNF in the blood is 
released from the brain or from other sources. To address this issue, Dawood and colleagues 
(2007) used direct blood sampling from the internal jugular vein and the brachial artery and 
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found that veno-arterial BDNF plasma concentration gradient acts as an index of brain 
BDNF production. Based on this determination, the veno-arterial BDNF concentration 
gradient was shown to be significantly reduced among patients at medium to high suicide 
risk compared to those at low risk. Additionally, this gradient was negatively correlated 
with suicide risk among untreated patients with depression. As such, BDNF level in sera or 
plasma appears to be decreased among suicidal individuals soon after attempted suicide, 
which is consistent with the changes observed in brain BDNF levels that have been reported 
in postmortem studies. These results suggest that BDNF may play an important role in the 
neurobiology of suicide and suicidal behavior in major depression. 
3.2 Other neurotrophic factors 
One study has found that BDNF and neurotrophin-3 (NT-3) levels are decreased in 
postmortem brains of suicide victims (Karege et al. 2005). Additionally, mRNA levels of 
nerve growth factor (NGF), NT-3, NT-4/5, cyclophilin, and neuron-specific enolase are 
decreased in the hippocampi of suicide victims (Dwivedi et al. 2005). Few studies have 
investigated other neurotropic factors, and further studies in suicidal depression are 
necessary.  
4. The hypothalamic–pituitary–adrenal (HPA) axis and cortisol 
The HPA axis is the major biological system involved in the acute stress response. The 
stress-related theory of depression states that chronic stress may lead to long-term activation 
of the HPA axis, which may then result in reductions in the volume or impairments to the 
function of the hippocampus (Holsboer 1988). Corticotropin-releasing hormone (CRH) 
levels in the CSF tend to be increased among suicide victims, suggesting an increase in HPA 
axis activity among individuals with suicidal behaviors (Arato et al. 1989). However, this 
association remains controversial and other research has shown that patients who make 
repeated suicide attempts may have even lower CSF CRH levels than patients who do not 
(Traskman-Bendz et al. 1992).  
The dexamethasone suppression test (DST) is one of the most useful assessments of HPA 
axis activity. During normal HPA axis activity, administration of dexamethasone, an 
exogenous synthetic glucocorticoid hormone, leads to negative feedback to the HPA axis. 
This negative feedback results in suppression of the release of adrenocorticotropic hormone 
(ACTH) from the hypothalamus, which results in suppression of the release of cortisol from 
the adrenal gland. The reduction in cortisol levels as measured in plasma results in a 
positive result on the DST test. Many studies have shown that cortisol non-suppression in 
response to the DST is a strong predictor of suicidal behavior (Coryell and Schlesser 2001; 
Kunugi et al. 2004; Yerevanian et al. 2004). Specifically, some reports have demonstrated 
that patients with non-suppression engage in more serious suicide attempts (Coryell 1990; 
Norman et al. 1990) or use more violent methods (Roy 1992) than those who do not exhibit 
non-suppression. Jokinen and Nordström (2008) found that DST non-suppression is 
associated with suicide attempts among young adult and elderly inpatients with mood 
disorders. However, Black and colleagues (2002) found no significant differences in the 
frequency of suicidal ideation or completed suicides between patients demonstrating DST 
suppression and those demonstrating non-suppression (Black et al. 2002). A long-term 
follow-up study spanning 15 years has shown that patients with depression and DST non-
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suppression have a roughly 14-fold higher risk of suicide than do patients with DST 
suppression (Coryell and Schlesser 2001). A meta-analysis estimated the odds ratio of 
suicide completion to be 4.5-fold greater among non-suppressors than suppressors in 
patients with mood disorders (Mann et al. 2006). Moreover, other long-term follow-up 
studies have suggested that the DST is a useful predictor of suicidal behaviors and attempts 
among individuals with mood disorders, depressed inpatients, and patients with manifest 
suicidality, but not among the general population (Jokinen et al. 2007) or in patients 
displaying DST suppression (Coryell et al. 2006). Further, Jokinen and colleagues (2008b) 
suggested that a different threshold for cortisol levels following dexamethasone may require 
defining DST non-suppression for the prediction of suicide among individuals experiencing 
melancholic depression. Yerevanian and colleagues (2004) also reported that DST non-
suppression identifies unipolar depressed patients at higher risk of future suicide 
completion or hospitalization for suicidality. Overall, evidence suggests that HPA axis 
hyperactivity may influence the overactivity of the adrenergic system and alternations of the 
serotonergic system (Mann 2003; Meijer and de Kloet 1998). 
5. Cholesterol 
Trials of cholesterol-lowering drugs revealed increased mortality due to accidents, violence, 
and suicide among subjects who received the drugs (Kaplan et al. 1997; Muldoon et al. 
1990). Kaplan and colleagues (1997) suggest that serum cholesterol reduction achieved by 
changing the serum composition or concentration of lipoproteins, could affect brain levels of 
fat-soluble micronutrient supply, structural lipids, cellular communication, or 
neurotransmitters, including serotonin. However, a second meta-analysis revealed only a 
modest, non-significant increase in deaths due to suicide and violence among patients 
receiving trials of dietary interventions and non-statin drugs (Muldoon et al. 2001).  
Clinical studies of psychiatric subjects indicate a relationship between lower total cholesterol 
levels and suicidal behavior. Specifically, it has been reported that suicide attempters tend to 
have significantly lower cholesterol levels than non-suicidal psychiatric inpatients and 
individuals experiencing accidental injuries (Kunugi et al. 1997). Plasma cholesterol levels 
among acutely suicidal patients with mood disorders were found to be lower than among 
non-suicidal inpatients with mood disorders and healthy subjects (Papassotiropoulos et al. 
1999). Additionally, a study of serum cholesterol levels showed that serum cholesterol is 
30% lower among violent suicide attempters, in comparison to non-violent suicide 
attempters and healthy subjects (Alvarez et al. 2000). Of note, studies of Korean subjects 
found that serum total cholesterol levels and densities of lipoproteins tend to be lower 
among parasuicidal individuals, and that serum triglyceride levels tend to be lower among 
suicide attempters than non-suicidal patients with major depressive disorder (Kim et al. 
2002a; Lee and Kim 2003). Moreover, our data suggest two cut-off points for serum 
cholesterol levels in patients with depression: 180 mg/dl, which may serve as a point for 
high sensitivity of possible risk of suicide, and 150 mg/dl, a point with a high specificity of 
probable risk of suicide (Kim and Myint 2004). However, studies in the general Korean 
population have failed to report consistent findings linking low cholesterol levels and 
suicidal behavior (Ellison and Morrison 2001; Iribarren et al. 1995). If suicidal behavior is 
associated with reductions in serum or plasma cholesterol levels, this may be explained 
because low cholesterol levels are related to decreased serotonin activity, which may 
increase tendencies toward impulsive, aggressive, and suicidal behavior (Heron et al. 1980; 
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Kaplan et al. 1997; Ringo et al. 1994). Another possible explanation is that decreased 
cholesterol in peripheral blood may reduce cholesterol levels in the brain, which may lead to 
reduced synaptic plasticity and brain dysfunction associated with impaired neurobehavioral 
consequences (Mauch et al. 2001; Pfrieger 2003).  
6. Nitric oxide and cytokines 
Nitric oxide (NO) is an endogenous gas that is known to influence cerebral monoaminergic 
activity, including serotonin activity (Montague et al. 1994; Yamada et al. 1995). In patients 
with major depression, the total amount and density of neurons with immunoreactivity to 
nitric acid synthase (NOS) were reduced in paraventricular neurons (Bernstein et al. 1998), 
and NOS activity was decreased in the prefrontal cortex (Xing et al. 2002). A previous study 
revealed that plasma NO levels were dramatically lower in patients with major depressive 
disorder compared to healthy controls (Chrapko et al. 2004). However, another study 
detected elevated NO levels in patients with major depression compared to patients with 
anxiety disorder and normal control subjects (Jozuka et al. 2003). We found that increased 
NO production in plasma is associated with suicide attempts in depressed patients (Kim et 
al. 2006).  
It has been postulated that major depression is accompanied by significant changes in cell-
mediated and humoral immunity and that these changes are related to the pathophysiology 
or pathogenesis of the illness (Miller and O'Callaghan 2005; Myint and Kim 2003; Schiepers 
et al. 2005). Pro-inflammatory cytokines including IL-1, IL-6, IL-12, and TNF- are 
increased in the blood in major depression (Kim et al. 2002b; Thomas et al. 2005; Tuglu et al. 
2003; Viljoen and Panzer 2005). These findings suggest that innate immunity is activated by 
secretion from monocytes and macrophages during major depression. A previous study 
measured cytokine secretion of T-cells of suicidal and non-suicidal depressed patients and 
healthy controls and found that the T-cells of suicidal depressed patients have Th1 
characteristics, while the T-cells of non-suicidal depressed patients have Th2 characteristics 
(Mendlovic et al. 1999). A new hypothesis concerning the relationships between serum 
lipids, depression, suicide and atherosclerosis suggests that IL-2 plays important roles in 
lipid metabolism, depression, suicide and atherosclerosis (Colin et al. 2003; Penttinen 1995). 
Our group found that Th1 and Th2 cytokine imbalances are observed in a subpopulation of 
depressed patients (Myint et al. 2005). We also found that Th1 cytokine (IL-2 and IL-6) levels 
were significantly lower in suicidal depressed patients than in non-suicidal depressive 
patients and normal controls (Kim et al. 2007a). Collectively, NO and cytokines may be 
candidates for biological markers of suicidal behavior in major depression, but they have 
not yet been investigated extensively.  
7. Can we predict suicidal behavior in major depression? 
Many studies have tried to identify biological etiologies and predictors of suicidal behavior 
in major depression, but this task has been difficult because most suicide risk factors have 
low specificity and the rate of suicide completion is relatively low the in the general 
population (Cohen 1986). These difficulties can be addressed when combinations of risk 
factors for suicide are used to estimate the suicide risk of individuals. For instance, several 
researchers have examined combinations of two biological risk factors for suicide 
simultaneously. Specifically, researchers have studied the coupling of CSF 5-HIAA and DST 
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non-suppression (Jokinen et al. 2008a; Jokinen et al. 2009; Mann et al. 2006) and the coupling 
of serum cholesterol and DST non-suppression (Coryell and Schlesser 2007). These 
combined factors may be useful because they reflect diverse aspects of suicidal phenomena. 
Specifically, Jokinen and colleagues (2008a) suggest that CSF 5-HIAA and DST non-
suppression are independent biomarkers and that CSF 5-HIAA may reflect short-term 
suicide risk, while dysregulation of the HPA axis may be a more long-term predictor of 
suicidal behavior. These findings appear to be even better predictors among individuals 
with major depression or with previous histories of attempted suicide. Mann and colleagues 
(2006) also suggested that low CSF 5-HIAA and serotonin dysfunction are markers of the 
diathesis and that DST non-suppression and HPA axis hyperactivity are markers of the 
acute stress response.  
Additionally, reduced cholesterol and BDNF levels in blood serum or plasma may be 
associated with impaired brain plasticity among individuals with suicidal behavior and 
ideation. In the future, it will be useful to examine multiple tests and risk factors, including 
CSF 5-HIAA, DST, cholesterol, and BDNF levels, as well as patient history of attempted 
suicide, in the prediction of suicide risk, especially among patients with depression.  
We propose a model that predicts suicide risk that also considers several factors. We based 
this model on the Child-Pugh classification system of severity of chronic liver disease (Pugh 
et al. 1973) and the model is presented in Table 1. Abnormal findings associated with 
serotonin or HPA activity are more significant among individuals with major depression or 
with previous histories of attempted suicide (Coryell and Schlesser 2007; Coryell et al. 2006). 
Additionally, an interaction effect of childhood abuse and gene polymorphisms of serotonin 
transporters and BDNF has also been reported to influence the risk for suicidal behavior 
(Currier and Mann 2008). Suicide is associated with dysfunction in the prefrontal cortex, 
which is related to poor executive function. Such dysfunction can be measured with the  
 
Parameter 
Points assigned 
0 1 2 3 
Childhood abuse history negative  positive  
Current depression negative positive   
Previous attempt 0 1  ≥ 2 
Genetic factors negative  positive  
CSF 5-HIAA > cut-off  ≤ cut-off  
DST suppression  Non-suppression  
BDNF levels normal  decreased  
Cholesterol levels (mg/dl) ≥ 180 180-150 < 150  
Wisconsin Card Sort Test Normal  Abnormal  
BDNF, brain-derived neurotrophic factor, DST, dexamethasone suppression test, CSF, cerebrospinal 
fluid, 5-HIAA, 5-hydroxyindoleacetic acid. Our hypothesis is that the total score of these parameters is 
correlated with current risk of suicide in major depression.  
Table 1. Proposed classification of multiple factors to explain risk of suicide in major 
depression. 
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Wisconsin Card Sorting Test, and reported deficits in executive functioning are associated 
with high-lethality suicidal attempts among individuals with major depression (Keilp et al. 
2001). Table 1 outlines nine risk factors for suicidal behavior and assigns one point to each 
factor. It is hypothesized that the total score of these risk factors is correlated with current 
risk of suicide.  
8. Conclusions 
Suicide is a complicated phenomenon that results from the interaction of several factors, 
including neurobiological changes, genetic predisposition, and psychological factors. 
Postmortem and clinical studies suggest that serotonin dysfunction is a form of diathesis or 
trait style-risk factor while HPA dysfunction is associated with stress response or state-
dependency. Decreased cholesterol and BDNF levels are also related to brain dysfunction 
among suicidal individuals. Decreased serotonin functioning among suicidal individuals 
has been measured with CSF 5-HIAA, fenfluramine challenge studies, and levels of platelet 
5-HT2A receptors. HPA axis dysfunction has been evaluated using the DST. Cholesterol and 
BDNF levels can be measured in blood serum or plasma. Additionally, serotonin 
dysfunction and lower BDNF activity has been found in the prefrontal cortex of the brain in 
suicidal individuals. Impairment in this region may be associated with behavioral 
disinhibition and executive dysfunctions, which is often examined with neurocognitive 
tests. We have proposed a model that incorporates present research on biological factors 
that may contribute to suicide risk. Clinical studies are needed to evaluate the validity of our 
risk scale for suicide, but we believe that based on current evidence, this provides a 
comprehensive screen. 
It remains challenging to identify neurobiological predictors of suicidal behavior that are 
promising and easily assessable. Since suicidal behavior is a complex phenomenon, a multi-
dimensional approach, including the above assessments, may be required to predict suicide 
risk, especially among individuals with major depression. A better understanding of the 
neurobiology of suicide in major depression will help detect at risk individuals or 
populations, and help develop better treatment interventions. 
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